Clinical Trial Update: Phase I Trial of GR1803 Injection in Patients With RRMM [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial update for GR1803 injection in relapsed/refractory multiple myeloma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GR1803 Injection (GR1803)

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Multiple Myeloma (MM) | Phase 1, Phase 2 | Status: COMPLETED